While Honda Sales Boomed In The U.S., Europe Was Allowed To Stagnate

इंडिया समाचार समाचार

While Honda Sales Boomed In The U.S., Europe Was Allowed To Stagnate
इंडिया ताज़ा खबर,इंडिया मुख्य बातें
  • 📰 Forbes
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 53%

Honda’s decision to shut its British factory was more a result of its lack of ambition in Europe rather than a need to restructure

हमने इस समाचार को संक्षेप में प्रस्तुत किया है ताकि आप इसे तुरंत पढ़ सकें। यदि आप समाचार में रुचि रखते हैं, तो आप पूरा पाठ यहां पढ़ सकते हैं। और पढो:

Forbes /  🏆 394. in US

इंडिया ताज़ा खबर, इंडिया मुख्य बातें

Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।

30 Under 30 Europe 2019: Art & Culture30 Under 30 Europe 2019: Art & CultureHow Conna Walker carved out her own path with House of CB: ForbesUnder30
और पढो »

The UK is the only country in Europe losing inbound tourismThe UK is the only country in Europe losing inbound tourismEven though demand for European destinations increased by six percent in 2018, the UK saw its inbound tourism taking a dive with a 5.3 percent decrease compared to 2017.
और पढो »

Should Europe uphold the right to return — even for Daesh families?Should Europe uphold the right to return — even for Daesh families?European powers are yet to claim their citizens, who want to return home from former Daesh-held territories in Syria, posing a significant question over whether the legal principle of the right to return will be applied.
और पढो »

Europe Again Champions Intervention to Counter China’s Economic MightEurope Again Champions Intervention to Counter China’s Economic MightEurope’s struggle to keep up with China’s government coordination of business and economic might of the U.S. has prompted more European politicians to advocate interventionism.
और पढो »

World’s best-selling drug costs five times more in U.S. than EuropeWorld’s best-selling drug costs five times more in U.S. than EuropeCritics accuse the maker of Humira of exploiting U.S. patent laws to keep competitors’ less expensive versions off the market. The company, AbbVie, says it’s balancing the need to keep the drug affordable to patients with the need to fund new drug development.
और पढो »



Render Time: 2025-02-28 21:31:34